Coronary/Structural Heart

Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure

MIAMI, Oct. 20, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use […]

OPTIMIZE Study Reports Lowest TLR Ever Achieved in an Investigational Device Exemption (IDE) Study With Svelte Medical System’s Bioresorbable Coated Drug-Eluting Coronary Stent

OPTIMIZE Pivotal Study 1 Year Outcomes Announced at TCT Connect NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–The Svelte® Drug-Eluting Stent (DES) achieved 1.5% clinically-driven Target Lesion Revascularization (TLR) at 1 year, the lowest ever reported in an Investigational Device Exemption (IDE) clinical study. Primary and secondary endpoint outcomes of the OPTIMIZE IDE study, designed […]

Cardiac Dimensions Announces up to 7.5 Year Data on the Carillon® Mitral Contour System

Have you seen the exciting new publication by Dr. Janusz Lipiecki and team, Long-term prognosis of patients treated by coronary sinus-based percutaneous annuloplasty: single centre experience, published in ESC Heart Failure 2020? This publication is Cardiac Dimension’s sixth this year! The company continues to release data which confirms the Carillon Mitral Contour System’s importance in the treatment of heart […]

CeloNova Announces Late-Breaking Evidence From First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT In Complex Patients At High Bleeding Risk Following PCI

The novel non-DES, non-BMS COBRA PzF NanoCoated Coronary Stent (NCS) with just 14-days DAPT demonstrated statistically less bleeding (BARC 1-5) compared to the DES arm at 3 or 6 months DAPT post-PCI, low 0.6% ST and low 3.7% ischemic-driven TLR at 6 months. SAN ANTONIO, Oct. 17, 2020 /PRNewswire/ —  CeloNova BioSciences, Inc. (CeloNova), […]

Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Cardiogenic Shock is Associated with Higher Survival, Particularly in Women

DANVERS, Mass.–(BUSINESS WIRE)–Two studies of AMI cardiogenic shock (AMICS) patients found higher survival when Impella was placed pre-PCI, compared to when Impella was placed after PCI. The findings were presented at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. In the first study, presented by Hemindermeet Singh, […]

Conformal Medical’s CLAAS® Stroke Prevention Technology Announces Promising Clinical Results at 2020 TCT Conference

U.S. and European feasibility studies demonstrate early success of novel conformable foam matrix implant for LAAC NASHUA, N.H., Oct. 15, 2020 /PRNewswire/ — Conformal Medical, Inc., a privately held medical device company developing next generation left atrial appendage closure (LAAC) technology, today announced positive clinical data from First-in-Human studies performed in the U.S. and Prague.  […]

Bracco Diagnostics Inc. Introduces New CardioGen-82® (Rubidium Rb 82 Generator) Infusion System

MONROE TOWNSHIP, N.J., Oct. 16, 2020 /PRNewswire/ — Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). […]

VASCEPA® (Icosapent Ethyl) Found to Significantly Reduce Ischemic Events in Patients with Prior Percutaneous Coronary Intervention (PCI) in Post Hoc Subgroup Analyses of Landmark REDUCE-IT® Study Presented at Transcatheter Cardiovascular Therapeutics (TCT) Connect 2020

VASCEPA®, compared with placebo, significantly reduced primary composite first and total MACE (major adverse cardiovascular events) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 34% Administration of VASCEPA resulted in robust absolute risk reductions of 8.5% and 5.4% and numbers needed to treat (NNT) of 12 and 19, respectively, for both […]

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

If approved, inclisiran will be the first and only small interfering RNA (siRNA) in Europe for patients with hypercholesterolemia or mixed dyslipidemia1 Cardiovascular disease (CVD) claims 3.9 million lives annually in Europe2, and 80% of high-risk patients do not reach guideline-recommended low-density lipoprotein cholesterol (LDL-C) targets despite the widespread use of statins3–5 Inclisiran provides effective and sustained reduction of LDL-C of up to […]

New Data Highlight a Significant Increase in Cardiovascular Treatment Efficiency when the HeartFlow Analysis is Incorporated into the Diagnostic Pathway

Nine-month results from FORECAST trial show statistically significant reduction in unnecessary invasive cardiac testing, increase in catheterization lab efficiency, and reduction in repeat non-invasive testing REDWOOD CITY, Calif.–(BUSINESS WIRE)–Late-breaking results presented today confirm that incorporating the HeartFlow® FFRct Analysis into a coronary computed tomography angiogram (CTA)-led diagnostic pathway significantly increases overall […]